Drugs / TILD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04314544 | Jul 2020 → Mar 2025 | psoriatic arthritis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-05-04 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis sunpharma.com ↗
Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, N SE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announce d that two pivotal Phase-3 clinical trials evaluating the effi cacy and safety of the investigational IL-23p19 inh ibitor antibody tildrakizumab (MK-3222) in patients with moderate-t o-severe plaque psoriasis met their primary endpoin ts for both evaluated doses. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-05-04 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis sunpharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TILD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04314544 ↗ |